Pfizer is ranked 1st in Australia/New Zealand region and overall 2nd in Asia in its corporate reputation from a patient perspective
Asian patient groups have placed the pharma industry 1st for corporate reputation in Asia amongst other healthcare sectors
Pfizer had been ranked first in its Covid-19 response, patient centricity, patient safety and bringing innovative, high-quality products amongst pharma companies in Asia in the ‘Corporate Reputation of Pharma’ survey by patient groups across the APAC region. Overall, the company is ranked second for its corporate reputation across Asian countries.
Pfizer moved up in the survey rankings from 4th place to occupy the top ranking in terms of patient groups ‘Working’ with Pfizer, representing a significant increase in rankings in 2021 vs. 2020, in ten Asian countries.
